ALLO-715

DB18640InvestigationalCell transplant therapies

ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
Curator reviewed
Also known as: Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)
Code names: ALLO-715

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with ALLO-715, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.